MUVienna
Vienna, 1090, Austria
NCT Number: NCT02930330
The purpose of this study is to determine whether high intensity interval training (INT) is more effective in suppressing platelet reactivity than continuous, moderate intensity training (CONT) in patients undergoing cardiac rehabilitation after percutaneous coronary intervention.
Looking for future studies?
Notify Me45 year and older
Male
Interventional
Not applicable
Vienna, 1090, Austria
Background: Platelets play an important role in cardiovascular disease: First, they promote the development of atherosclerotic lesions, and second, platelets form vessel occluding thrombi on top of (ruptured) lesions, ultimately leading to thrombotic events like myocardial infarctions (MCI). Whereas acute, strenuous exercise causes platelet activation and transiently increases the risk for MCIs, long-term chronic exercise training results in a clear reduction of both platelet activation and MCI incidence.
Exercise training plays a key role in cardiac rehabilitation, since improvements in cardiorespiratory fitness (CRF) are associated with decreased mortality in these patients. With respect to CRF improvements, high-intensity interval training has been demonstrated to be more effective than moderate-intensity continuous exercise. However, the beneficial effect of high-intensity interval training on platelet function in patients with cardiovascular disease has never been investigated.
Scientific question: The aim of this study is to determine the effect of interval training in cardiac rehabilitation on platelet function.
Hypotheses: Cardiac rehabilitation with interval training components (INT) reduces
Work program: 80 patients at the beginning of phase II cardiac rehabilitation will be randomly assigned to an interval group or to a control group. In both groups, patients will exercise 4x / week for 12 weeks. At the beginning, after 6 weeks and at the end an exercise test will be carried out. Blood will be taken before (platelet function at rest) and immediately after each exercise test (platelet function after acute, strenuous exercise). Basal platelet activation as well as platelet responsiveness towards a platelet agonist (platelet reactivity) will be analyzed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Pmax*: Maximal power output (Watt) achieved at the end of an incremental exercise test.
Other names: High intensity interval training
Pmax*: Maximal power output (Watt) achieved at the end of an incremental exercise test.
Other names: Moderate intensity continuous training
Time frame: 6 weeks
Platelet reactivity as measured by half maximal effective concentration (EC50) of the platelet agonist TRAP-6 (Thrombin receptor activating peptide-6; SFLLRN) in terms of platelet CD62P (P-selectin) expression, as described in Heber et al. 2016 (PMID: 26909532). The percentage of CD62P expressing platelets is quantified by flow cytometry without and with increasing concentrations of the platelet agonist TRAP-6. EC50 of TRAP-6 is estimated by fitting a four parameter logistic dose-response curve to flow cytometry data as a function of agonist concentration, aggregating multiple measurements to one reported value (EC50) with the unit µM.
Treatment effects on platelet reactivity at physical rest after 6 weeks (INT vs. CONT) are estimated by ANCOVA, with baseline values as covariate.
Time frame: 12 weeks
Platelet reactivity as measured by half maximal effective concentration (EC50) of the platelet agonist TRAP-6 (Thrombin receptor activating peptide-6; SFLLRN) in terms of platelet CD62P (P-selectin) expression. The percentage of CD62P expressing platelets is quantified by flow cytometry without and with increasing concentrations of the platelet agonist TRAP-6. EC50 of TRAP-6 is estimated by fitting a four parameter logistic dose-response curve to flow cytometry data as a function of agonist concentration, aggregating multiple measurements to one reported value (EC50) with the unit µM.
Treatment effects on platelet reactivity at physical rest after 12 weeks (INT vs. CONT) are estimated by ANCOVA, with baseline values as covariate.
Time frame: 6 weeks
Maximal power output (Watt / kg bodyweight) at the end of an incremental exercise test
Time frame: 12 weeks
Maximal power output (Watt / kg bodyweight) at the end of an incremental exercise test
Time frame: 6 weeks
Maximal oxygen consumption (ml/min/kg bodyweight) at the end of an incremental exercise test
Time frame: 12 weeks
Maximal oxygen consumption (ml/min/kg bodyweight) at the end of an incremental exercise test
Medical University of Vienna
Other
Interval Training in Cardiac Rehabilitation: Effects on Cardiorespiratory Fitness and Platelet Function - A Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01232608
Arterial Occlusive Diseases, Arteriosclerosis
Oslo, Norway
View Trial DetailsNCT07625488
Arterial Occlusive Diseases, Arteriosclerosis
Nijmegen, Netherlands
View Trial DetailsNCT06508437
Arterial Occlusive Diseases, Arteriosclerosis
Tours, France
View Trial DetailsNCT04382443
Acute Coronary Syndrome, Arterial Occlusive Diseases
Ciudad de Buenos Aires, Buenos Aires, Argentina
View Trial Details